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Association of Age, Antipsychotic Medication, and Symptom Severity
in Schizophrenia With Proton Magnetic Resonance Spectroscopy
Brain Glutamate Level
A Mega-analysis of Individual Participant-Level Data
Kate Merritt, PhD; Philip K. McGuire, FMedSci; Alice Egerton, PhD; and the 1H-MRS in Schizophrenia Investigators
IMPORTANCE Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that
altered brain glutamatergic function may be associated with the pathophysiology of
schizophrenia and the response to antipsychotic treatment. However, the association
of altered glutamatergic function with clinical and demographic factors is unclear.
OBJECTIVE To assess the associations of age, symptom severity, level of functioning,
and antipsychotic treatment with brain glutamatergic metabolites.
DATA SOURCES The MEDLINE database was searched to identify journal articles published
between January 1, 1980, and June 3, 2020, using the following search terms: MRS or
magnetic resonance spectroscopy and (1) schizophrenia or (2) psychosis or (3) UHR or (4)
ARMS or (5) ultra-high risk or (6) clinical high risk or (7) genetic high risk or (8) prodrome* or
(9) schizoaffective. Authors of 114 1H-MRS studies measuring glutamate (Glu) levels in
patients with schizophrenia were contacted between January 2014 and June 2020
and asked to provide individual participant data.
STUDY SELECTION In total, 45 1H-MRS studies contributed data.
DATA EXTRACTION AND SYNTHESIS Associations of Glu, Glu plus glutamine (Glx), or total
creatine plus phosphocreatine levels with age, antipsychotic medication dose, symptom
severity, and functioning were assessed using linear mixed models, with study as
a random factor.
MAIN OUTCOMES AND MEASURES Glu, Glx, and Cr values in the medial frontal cortex (MFC)
and medial temporal lobe (MTL).
RESULTS In total, 42 studies were included, with data for 1251 patients with schizophrenia
(mean [SD] age, 30.3 [10.4] years) and 1197 healthy volunteers (mean [SD] age, 27.5 [8.8]
years). The MFC Glu (F1,1211.9 = 4.311, P = .04) and Glx (F1,1079.2 = 5.287, P = .02) levels were
lower in patients than in healthy volunteers, and although creatine levels appeared lower in
patients, the difference was not significant (F1,1395.9 = 3.622, P = .06). In both patients and
volunteers, the MFC Glu level was negatively associated with age (Glu to Cr ratio,
F1,1522.4 = 47.533, P < .001; cerebrospinal fluid–corrected Glu, F1,1216.7 = 5.610, P = .02),
showing a 0.2-unit reduction per decade. In patients, antipsychotic dose (in chlorpromazine
equivalents) was negatively associated with MFC Glu (estimate, 0.10 reduction per 100 mg;
SE, 0.03) and MFC Glx (estimate, −0.11; SE, 0.04) levels. The MFC Glu to Cr ratio was
positively associated with total symptom severity (estimate, 0.01 per 10 points; SE, 0.005)
and positive symptom severity (estimate, 0.04; SE, 0.02) and was negatively associated with
level of global functioning (estimate, 0.04; SE, 0.01). In the MTL, the Glx to Cr ratio was
positively associated with total symptom severity (estimate, 0.06; SE, 0.03), negative
symptoms (estimate, 0.2; SE, 0.07), and worse Clinical Global Impression score (estimate,
0.2 per point; SE, 0.06). The MFC creatine level increased with age (estimate, 0.2; SE, 0.05)
but was not associated with either symptom severity or antipsychotic medication dose.
CONCLUSIONS AND RELEVANCE Findings from this mega-analysis suggest that lower brain Glu
levels in patients with schizophrenia may be associated with antipsychotic medication
exposure rather than with greater age-related decline. Higher brain Glu levels may act
as a biomarker of illness severity in schizophrenia.
JAMA Psychiatry. 2021;78(6):667-681. doi:10.1001/jamapsychiatry.2021.0380
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G lutamatergic dysfunction is implicated in the patho-physiology of schizophrenia,1,2 but the nature of thisdysfunction may change over the course of illness.2,3
Aspects of glutamatergic dysfunction can be investigated in
vivo using proton magnetic resonance spectroscopy (1H-
MRS), which measures the total amount of intracellular and
extracellular glutamate (Glu) in a predefined voxel of inter-
est. Meta-analyses of 1H-MRS studies indicate that glutamater-
gic metabolites are elevated in patients with schizophrenia
compared with healthy volunteers2; however, a recent meta-
analysis of 7-T MRS studies reports lower Glu levels in patients,4
and individual studies show variable results. This heteroge-
neity may be associated with factors such as age, illness du-
ration, symptom severity, illicit substance use, and antipsy-
chotic medication exposure, which vary between cohorts. The
associations of such factors are best examined in large data sets
incorporating patients across different stages of illness.
There is some indication that elevations in 1H-MRS gluta-
matergic metabolite levels may be most apparent in early
psychosis5-8 but reduced in chronic schizophrenia.9-14 This
finding may be associated with the expression of dysfunc-
tional compensatory processes that emerge secondary to the
illness15 but may also be associated with other factors (eg,
divergence from normal aging processes or medication expo-
sure lasting many years). Large studies have not yet reached a
consensus on the associations of aging with Glu levels in pa-
tients with schizophrenia. An age-related decrease in medial
frontal cortex (MFC) Glu level has been observed in both pa-
tients and healthy volunteers,16 but these findings were not
replicated by another large study.17 Alternatively, metaregres-
sion analysis has detected accelerated MFC glutamatergic re-
ductions in patients with schizophrenia compared with healthy
volunteers,18-20 but this finding was not apparent in a more re-
cent analysis.2 Metaregression analyses are limited to using
group mean data extracted from individual studies, and thus
it is difficult to disentangle age-dependent associations from
other clinical factors that correlate with age, such as the du-
ration of illness or the duration of antipsychotic treatment. In-
deed, a number of longitudinal studies have reported reduc-
tions in brain glutamatergic metabolite levels following
antipsychotic treatment in the frontal and temporal lobes
among other regions.21
There is also a lack of consensus about whether brain glu-
tamatergic metabolite levels are associated with symptom se-
verity and global functioning. A systematic review found in-
consistent evidence to correlate Glu levels to symptom
severity,22 although many studies were limited by small sample
sizes of patients with similar symptom profiles. Individual stud-
ies comparing symptomatic and nonsymptomatic patients have
reported higher Glu plus glutamine (Glx) levels in the symp-
tomatic group23 and elevated Glu levels in nonremitted pa-
tients compared with remitted patients.24-26 However, age may
confound these associations if patients with more severe
symptoms are younger.
With the aim of better characterizing glutamatergic dys-
function in schizophrenia, we conducted a mega-analysis of
individual participant–level data examining the associations
of age, antipsychotic medication exposure, diagnosis, symp-
tom severity, and functioning with 1H-MRS measures of glu-
tamatergic metabolite levels. We hypothesized that (1) gluta-
matergic metabolite levels would decrease in association with
age in both healthy volunteers and patients; (2) glutamater-
gic metabolite levels would be associated with a decrease in
the context of higher antipsychotic medication doses; (3) glu-
tamatergic metabolite levels would be lower in patients than
in healthy volunteers; and (4) more severe symptoms and
worse global functioning would be associated with higher Glu
levels. In addition, we tested the assumption that these fac-
tors are not associated with the combined creatine and phos-
phocreatine signal (Cr) because Glu is commonly reported in
ratio to Cr for analyses.
Methods
The MEDLINE database was searched to identify journal ar-
ticles published between January 1, 1980, and June 3, 2020,
using the following search terms: MRS or magnetic reso-
nance spectroscopy and (1) schizophrenia or (2) psychosis or
(3) UHR or (4) ARMS or (5) ultra-high risk or (6) clinical high
risk or (7) genetic high risk or (8) prodrome* or (9) schizoaf-
fective. Authors of 1H-MRS studies were contacted at least twice
between January 2014 and June 2020 to request anony-
mized participant-level 1H-MRS metabolite data, which in-
cluded levels of Glu, glutamine, Glx, and Cr and Cramér-Rao
Lower Bound values, which estimate metabolite goodness of
fit.27 Clinical and demographic data included positive, nega-
tive, general, and total subscores of the Positive and Negative
Syndrome Scale (PANSS), Global Assessment of Functioning
(GAF) scores, Clinical Global Impression (CGI) scores, age,
duration of illness, antipsychotic medication dose, and dura-
tion of treatment. All methods and results are reported
following the Preferred Reporting Items for Systematic Re-
views and Meta-analyses (PRISMA) reporting guideline.
Analyses were restricted to variables for which a mini-
mum of 3 independent data sets were available.28 Brain me-
tabolite data were categorized into (1) the MFC, including the
Key Points
Question Are clinical and demographic factors associated with
brain glutamate or glutamate plus glutamine (Glx) levels in
schizophrenia?
Findings In this mega-analysis of 1251 patients with schizophrenia
and 1197 healthy volunteers, medial frontal cortex glutamatergic
metabolite levels were lower in patients and negatively associated
with the dose of antipsychotic medication, although a reduction in
glutamate levels with age was not accelerated in patients with
schizophrenia compared with healthy individuals. Higher medial
frontal cortex and medial temporal lobe glutamate levels were
associated with more severe symptoms in patients with
schizophrenia.
Meaning Lower brain glutamate levels may be associated with
antipsychotic exposure rather than with greater age-related
decline, whereas higher glutamate levels may serve as a biomarker
of illness severity in patients with schizophrenia.
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anterior cingulate cortex and (2) medial temporal lobe (MTL),
including the hippocampus. Data with Cramér-Rao Lower
Bound values higher than 20% were excluded. Glutamate val-
ues are often corrected for the amount of cerebrospinal fluid
(CSF) in the voxel because CSF contains negligible metabo-
lites of interest. Alternatively, Glu is estimated relative to Cr.
Herein, CSF-corrected and Cr-scaled values were aggregated
separately.
Associations of Glu, Glx, or creatine levels with variables
of interest were assessed using linear mixed models in R, ver-
sion 3.6 (R Core Team),29 with the lmer and ggplot2 packages.30
Independent variables were entered as fixed factors, and study
was entered as a random factor. Glutamate and Glx measures
are not independent and thus were not corrected for multiple
comparisons. Tests of collinearity determined which vari-
ables to include in the model. For analyses investigating the
association of age with metabolites, model 1 investigated the
direct association of age plus group (patient vs healthy volun-
teers), and model 2 assessed their interaction. The linear mixed
models were estimated with maximum likelihoods because
residual likelihoods are not comparable across models with
different fixed effects.31 The lowest Akaike information crite-
rion value indicates the best model,28 and χ2 tests were used
to assess which model was superior. To determine whether me-
tabolite values in patients were best estimated by age or with
chlorpromazine equivalent (CPZE) dose (when both were sig-
nificantly associated with metabolite levels), model 1 in-
cluded CPZE dose, and model 2 included both age and CPZE
dose.
For symptom severity, we reduced the number of com-
parisons by first testing the association between metabolite lev-
els and PANSS total score. When the association was signifi-
cant, follow-up analyses investigated the PANSS positive and
negative score in one model with restricted maximum
likelihoods.28 To investigate the association between Glu level
and functioning, GAF scores were examined. If GAF scores were
unavailable, then CGI scores were examined. To determine
whether patient metabolite values were best estimated by age
or by PANSS total scores, model 1 included PANSS total scores,
and model 2 included both age and PANSS total scores. For all
comparisons, a 2-sided P < .05 was considered statistically sig-
nificant.
Results
The literature search identified 114 studies (eFigure in the
Supplement). Of those studies, 45 contributed data (eTable 1
in the Supplement). Two of these studies were not included
because data were only available for ultra-high-risk
participants,32,33 and 1 study was excluded because 1H-MRS
was conducted using a J-resolved acquisition approach.34 A
total sample size of 1251 patients with schizophrenia (mean [SD]
age, 30.3 [10.4] years) and 1197 healthy volunteers (mean [SD]
age, 27.5 [8.8] years) were included in the analyses. Sample
sizes from each study ranged from 10 to 89 healthy volun-
teers and from 10 to 147 patients. Twenty-four studies
examined patients with first-episode psychosis,5,7,11,24,35-53
and 20 studies examined patients with established
schizophrenia.11,14,25,35,36,38-40,44,54-63 Four studies did not
include healthy volunteer data.24,32,61,64
Association of Demographic and Clinical Factors
With Cr Level
In the MFC, Cr levels increased with age (F1,1399.1 = 20.678,
P < .001; n = 1417) (Figure 1) at a rate of 0.2 units per decade
(SE = 0.05). This association did not differ between patients
and healthy volunteers (Table 1). In the MTL, there was no
association between Cr level and age. There were no signifi-
cant associations of Cr level with CPZE dose, PANSS total symp-
toms, or GAF score in either the MFC or MTL.
Association of Age and CPZE Dose
With Glutamatergic Metabolite Levels
Duration of illness was associated with age and therefore was
not included in the model. Age was not significantly associ-
ated with CPZE dose (eTable 2 in the Supplement).
Across all participants, MFC Glu levels decreased with age
(Glu to Cr ratio: F1,1522.4 = 47.533, P < .001; n = 1534; CSF-
corrected Glu level: F1,1216.7 = 5.610, P = .02; n = 1226) (Figure 1).
The Glu to Cr ratio decreased by 0.04 units per decade
(SE = 0.006), and CSF-corrected Glu levels decreased by 0.2
units per decade (SE = 0.07). There was no interaction be-
tween age and group (Table 1). The MFC Glx to Cr ratio also de-
creased with age (F1,1345.4 = 15.685, P < .001; n = 1357), by 0.04
units per decade (SE = 0.01). The MFC CSF-corrected Glx level
was not significantly associated with age.
Both the MFC CSF-corrected Glu and CSF-corrected Glx lev-
els were negatively associated with CPZE dose (CSF-
corrected Glu level: F1,269.3 = 7.583, P = .006, n = 276; CSF-
corrected Glx level: F1,251.3 = 6.326, P = .01, n = 259) (Figure 2).
The CSF-corrected Glu level decreased by 0.10 per 100 mg of
the CPZE dose (SE = 0.03), and the CSF-corrected Glx level de-
creased by 0.11 per 100 mg of the CPZE dose (SE = 0.04). The
associations of the CPZE dose with the Glu to Cr and Glx to Cr
ratios were nonsignificant.
When assessing the association of age with CPZE dose in
the same model, the model combining age and CPZE dose best
estimated the MFC CSF-corrected Glu level (Table 1). In con-
trast to the MFC, in the MTL, the Glx to Cr ratio was not sig-
nificantly associated with age (n = 143 patients with schizo-
phrenia, n = 151 healthy volunteers) or with CPZE dose (n = 94).
There were insufficient data to examine the Glu to Cr ratio,
the CSF-corrected Glu level, or the CSF-corrected Glx level in
the MTL.
Associations With Group
Both MFC CSF-corrected Glu and CSF-corrected Glx levels
were lower in the schizophrenia group compared with the
healthy volunteer group while controll ing for age
(F1,1211.9 = 4.311, P = .04, n = 596 healthy volunteers, n = 630
patients with schizophrenia; F1,1079.2 = 5.287, P = .02, n = 519
healthy volunteers, n = 573 patients with schizophrenia)
(Table 1). There was no association of group with MFC Glu
to Cr ratio or Glx to Cr ratio. However, although not statisti-
cally significant, MFC Cr levels were lower in patients com-
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pared with healthy volunteers while controlling for age
(F1,1395.9 = 3.622, P = .06, n = 712 healthy volunteers, n = 705
patients with schizophrenia). In the MTL, the Cr level and
the Glx to Cr ratio did not differ between patients and
healthy volunteers.
Association Between Glutamatergic Metabolite Levels
and Symptom Severity
The PANSS total, positive, general, and negative subscores were
all intercorrelated (eTable 2 in the Supplement); therefore,
the initial model examined the PANSS total score. When sig-
nificant, follow-up analyses investigated the PANSS positive
score and the PANSS negative score in 1 model.
The MFC Glu to Cr ratio was positively associated with
the PANSS total score (F1,659.1 = 5.819, P = .02, n = 668)
(Figure 3). The Glu to Cr ratio increased by 0.01 per 10 points
on the PANSS scale (SE = 0.005). Subsequent analysis found
a positive association between the Glu to Cr ratio and the
PANSS positive score (F1,615.7 = 4.382, P = .004, n = 625),
whereby the Glu to Cr ratio increased by 0.04 per 10 points
(SE = 0.02). The PANSS negative score was nonsignificant.
The MFC Glu to Cr ratio was negatively associated with the
GAF score (F1,171.8 = 13.152, P < .001, n = 178) (Figure 3), such
that the Glu to Cr ratio increased by 0.04 per 10-point reduc-
tion on the GAF scale (SE = 0.01). There were no associations
of CSF-corrected Glu or Glx level with the PANSS total or
GAF score (Table 2).
The MTL Glx to Cr ratio was positively associated with
the PANSS total score (F1,128.7 = 4.508, P = .04, n = 132)
(Figure 3). The Glx to Cr ratio increased by 0.06 per 10 points
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F1,1216.7 = 5.610, P < .02
A, MFC glutamate to creatinine plus phosphocreatine ratio (Glu/Cr). B, Cerebrospinal fluid (CSF)–corrected Glu levels. C, MFC Glu plus glutamine to Cr ratio (Glx/Cr).
D, Cr levels. Glu and Glx levels in the MFC decrease with age in patients and healthy volunteers. Cr levels in the MFC increase with age in patients and healthy
volunteers. Lines represent the linear mixed model for patients and healthy volunteers, with SEs represented by the gray shaded areas. The CSF-corrected Glu levels
and the Cr levels are in arbitrary units.
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Table 1. Association of Age and Antipsychotic Medication With Glutamatergic Metabolite Levels and Total Creatine Plus Phosphocreatine Levels
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Diagnosis
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Est (SE) −0.0229 (0.0083)
Diagnosis
F1,1209.9 = 0.441, P = .51
Age × diagnosis



































































F1,1339.3 = 0.650, P = .42
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(SE = 0.03). Subsequent analysis found a positive association
between the Glx to Cr ratio and the PANSS negative score
(F1,129.8 = 10.162, P = .002, n = 132), such that the ratio
increased by 0.2 per 10 points (SE = 0.07). No significant
association was found for the PANSS positive score. The GAF
data were unavailable. A higher Glx to Cr ratio was associ-
ated with a worse CGI score (F1,73.0 = 10.914, P = .002,
n = 76), whereby the ratio increased by 0.2 per point on the
CGI scale (SE = 0.06).
In the MFC, the PANSS total score was negatively associ-
ated with age, such that younger patients had more severe
symptoms (eTable 2 in the Supplement). We compared
whether the variance in the Glu to Cr ratio was best
explained by age, PANSS total score, or both. The model
including both age and PANSS total score showed the best fit
(Table 2). The PANSS total score and CPZE dose were posi-
tively associated in the mega-analysis sample, such that
patients with more severe symptoms received a higher CPZE
dose (eTable 2 in the Supplement).
Discussion
We conducted a participant-level mega-analysis to assess
the association between 1H-MRS glutamatergic metabolite
levels and the clinical and demographic features of schizo-
phrenia. The main findings were negative associations of
glutamatergic metabolite levels in the MFC with age in both
patients with schizophrenia and healthy individuals and
with the dose of antipsychotic medication in patients.
Higher MFC Glu to Cr ratios were associated with more
severe total and positive symptoms and with a lower level of
overall functioning. In the MTL, elevated Glx to Cr ratios
were associated with more severe total and negative symp-
Table 1. Association of Age and Antipsychotic Medication With Glutamatergic Metabolite Levels and Total Creatine Plus Phosphocreatine Levels
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F1,1082.5 = 0.472, P = .49
Diagnosis
F1,1077.6 = 1.321, P = .25
Age × diagnosis










































F1,270.5 = 1.755, P = .19
Diagnosis
F1,270.3 = 0.036, P = .85
Age × diagnosis




































F1,293.7 = 2.074, P = .15
Diagnosis
F1,290.6 = 0.396, P = .53
Age × diagnosis


















Abbreviations: AIC, Akaike information criterion; CPZE, chlorpromazine equivalent dose; Cr, creatine plus phosphocreatine; CSF, cerebrospinal fluid; Est, estimate;
Glx, glutamate plus glutamine; HV, healthy volunteers; NA, not applicable; P, patients.
a If age and CPZE dose are significantly associated with glutamatergic metabolites, then model 1 including CPZE is compared with model 2 including both CPZE
and age. When χ2 test for model comparison is not significant, then the simplest model is selected.
b Determined by use of the χ2 test.
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toms and with worse CGI scores. In patients, MFC Glu levels
were lower than in healthy volunteers irrespective of age,
and there was a nonsignificant trend for lower Cr levels in
patients. In the MFC, Cr levels, a measure commonly
thought to be independent of age, increased with age in both
patients and healthy volunteers. Overall, these results indi-
cate that higher Glu levels may be associated with greater ill-
ness severity but that Glu levels may be reduced through
effective antipsychotic treatment to below those observed in
healthy volunteers.
The finding that MFC Glu levels decrease with age in pa-
tients with schizophrenia in a manner similar to healthy vol-
unteers suggests that these reductions may reflect normal ag-
ing processes in this brain region (2%-3% reduction of mean
Glu metabolite per decade). This is consistent with a recent
meta-analysis of brain Glu metabolite levels in normal aging,
which reports a larger effect size for Glu than Glx for age, as
glutamine (part of the Glx signal) increases with age.71 In con-
trast to that meta-analysis, our mega-analysis did not detect
changes associated with age in the MTL. This inconsistency
may be due to the smaller number of studies available in this
brain region, limiting our analysis to Glx levels and preclud-
ing assessment of Glu levels. One previous metaregression ob-
served an accelerated effect of aging in patients compared with
healthy volunteers20; however, this association may have been
caused by a group of patients at ultra-high risk. Therefore, re-
duced Glu levels in patients compared with healthy volun-
teers in previous reports may not have been caused by greater
age-related decline.
Conversely, MFC Cr levels increased with age in both
patients and healthy volunteers (2% increase of mean Cr
level per decade), consistent with previous studies,72-75
although 1 study reports no association.76 Creatine and
phosphocreatine are involved in energy metabolism, and
increased levels may reflect more burden on this system or
increased glial cell numbers and activation with age.77,78
Caution should be taken when using Cr as a reference
metabolite in the MFC because there was a trend for lower
levels in patients. This lower level may have masked Glu dif-
ferences between cases and controls, and thus lower patient
Glu levels were detected only for CSF-corrected metabolites.
Our findings are consistent with a report that the anterior
cingulate cortex Cr level is negatively associated with schizo-
phrenia spectrum liability.79 Therefore, future studies
should prioritize CSF-corrected measures.
Our finding of lower MFC glutamatergic metabolite lev-
els in patients with schizophrenia relative to healthy volun-
teers is consistent with a recent meta-analysis.4 Our study
indicates that age and antipsychotic medication were inde-
pendently associated with MFC Glu levels because the
model incorporating both of these uncorrelated measures
showed the best fit. This result suggests that findings of
reduced Glu levels in patients compared with healthy volun-
teers are not associated with accelerated aging in patients
but may be explained by greater antipsychotic exposure,
although lower Glu levels have been reported in minimally
treated patients with first-episode psychosis.80,81 This find-
ing may explain reports of reduced anterior cingulate cortex
Glu levels in patients with chronic schizophrenia compared
with healthy volunteers.9-14 Indeed, a large longitudinal
study reports a decrease in Cr-scaled Glu levels with
treatment.5 Antipsychotic medication may reduce Glu levels
indirectly, secondary to a reduction in dopaminergic signal-
ing via striatal-cortical feedback loops.82 Studies indicate
that this result is not necessarily associated with symptom
improvement5,49,83 and that Glu levels remain elevated in











CPZE dose equivalent, mg
Glu level vs CPZE doseA
30000 1000 2000










CPZE dose equivalent, mg
Glx level vs CPZE doseB
30000 1000 2000
F1,251.3 = 6.326, P = .01
Bustillo et al,7 2010
Demjaha et al,64 2014
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A, Cerebrospinal fluid (CSF)–corrected glutamate (Glu) levels.7,11,14,24,38,40,42,44,45,65 B, CSF-corrected Glu plus glutamine (Glx) levels.7,11,14,24,38,40,42,44,65
The black line represents the linear mixed model, with SE represented by the gray shaded areas; the random-intercept models for each study listed are shown in
different colors.
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patients nonresponsive to treatment, despite higher or simi-
lar doses of medication.5,24,25,65,84-86
Our third finding was that higher glutamatergic metabolite
levels in both the MFC and MTL were associated with more se-
vere symptoms and lower functioning. In the sample, younger
patients were more likely to have severe symptoms, and the
model incorporating both age and symptoms provided the best
fit for the Glu data. Patients with more severe symptoms received
a higher CPZE dose; thus, the association of symptoms with Glu
level is not better explained by medication exposure. When
symptomdimensionsweresubsequentlyexamined,Glumetabo-
lite levels in the MFC were associated with positive symptoms,
whereas those in the MTL were associated with negative symp-
toms. The MFC and MTL are key brain regions implicated in
schizophrenia. Glutamatergic outputs from these regions regu-
late dopamine release in the striatum, and excess dopamine
Figure 3. Correlations Between Medial Frontal Cortex (MFC) and Medial Temporal Lobe (MTL) Glutamatergic Metabolites
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release may underlie the development of psychotic symptoms.87
Hippocampal Glu level alterations may also be associated with
learning and memory,88 relevant to negative symptoms. Asso-
ciations with symptoms were observed for Cr-scaled but not




The strengths of the present study include the large patient
sample (more than 700 patients), which enabled linear mixed
models to account for potential collinearity. Mega-analyses are
reported to be more sensitive than meta-analyses owing to
narrower confidence intervals.89 Because data were as-
sembled from different countries, the sample represents vary-
ing demographic features and clinical treatments.
The process of combining data from multiple indepen-
dent sites also has limitations. The 1H-MRS acquisition proto-
cols, MR imaging platforms, and scaling methods differed
among studies, which we controlled for in the analysis by using
linear mixed models to control for site effects and by sepa-
rately considering CSF-corrected data from Cr-scaled data. Ide-
ally, future prospective multicenter studies would further har-
monize 1H-MRS acquisition and correction methods to enable
more reliable data synthesis.90 Nevertheless, harmonization
will always be constrained by the use of different MR imaging
platforms across centers. Despite using established rating
scales, there is a possibility of site effects associated with clini-
cal assessment scores and CPZE dose calculations. Owing to
a lack of data, we were unable to examine other brain regions
that may be associated with schizophrenia pathophysiology.
Therefore, we cannot determine whether the observed asso-
ciations extend to other brain regions. The CPZE dose was not
available for all studies; thus, analyses were restricted to
smaller samples. Our analysis of the association between medi-
cation and Glu levels relied on cross-sectional data. Longitu-
dinal studies can better examine the causal association be-
tween these factors, but our results are consistent with
longitudinal studies reporting reduced MFC glutamatergic me-
tabolite levels with treatment.5,39,49,83,91,92 Antipsychotic dose
was associated with CSF-corrected Glu metabolite levels but
not with Cr-scaled values. This finding contrasts with a large
longitudinal 1H-MRS study finding a reduction in Cr-scaled Glu
level with treatment.5 Finally, mega-analyses rely on contrib-
uted data, resulting in data omission.
Conclusions
These findings have important implications for MRS studies
in schizophrenia. They highlight the value of matching or ad-
justing for age, prioritizing CSF-corrected measures over Cr-
scaled metabolite levels, and considering antipsychotic dose
as an explanatory factor when comparing Glu levels between
patients and healthy volunteers. The finding of elevated Glu
levels in patients with more severe symptoms provides fur-
ther support for the use of glutamatergic measures as a po-
tential biomarker of illness severity, alongside other mea-
sures, and the development of novel treatments that target
brain glutamatergic function.
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